In addition, alpelisib, an alpha-specific PI3K inhibitor (PI3Ki), has recently been approved for the treatment of PIK3CA-mutated ER+ advanced breast cancer that progressed on previous endocrine therapy17. This evidence concerns the gene ESR1 and breast cancer.